Management define Akanocure's mission as synthesisand development of biotargeted anti-cancer chemotherapeutic drugs derived from natural sources. The firm's pipeline is intended to consist of analogs of fully validated, highly potent anti-cancer natural products that can only be produced on a large scale through Akanocure's proprietary CCC synthesis platform. Organized around certain bio-inspired, second generation small molecules (SGSM) as a breakthough therapeutic for orphan, unmet needs in cancer, the firm's drug design is enabled by a synthesis platform that has made readily available compounds that were not previously attainable. SGSMs are a group of novel bio-inspired anti-cancer drugs that are designed to have the affinities and elicit the protein-protein interaction (PPI) modulation of macromolecules while retaining the high tumor permeability of small molecules. SGSMs are designed to be inexpensive to develop, avoid the side effects of chemotherapy, elicit response in most patients, suppress metastasis, and prolong remission. Some SGSMs could have synergistic effect when combined with immunotherapies. The firm's patented "Chiral Carbon Catalog" platform enables synthesizis of the building blocks that can be combined to produce a library of analogs of those complex SGSMs. The firm has synthesized those building blocks on a large scale. Importantly, this has achieved highly cost effectvely by requiring fewer steps and using less expensive starting materials than any other synthesis to date.
